Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

255.16
+4.251.69%
Volume:2.66M
Turnover:672.45M
Market Cap:450.97B
PE:72.09
High:255.25
Open:251.23
Low:249.74
Close:250.91
52wk High:267.47
52wk Low:190.75
Shares:1.77B
Float Shares:1.76B
Volume Ratio:0.62
T/O Rate:0.15%
Dividend:6.83
Dividend Rate:2.68%
EPS(TTM):3.54
EPS(LYR):2.36
ROE:6225.00%
ROA:10.51%
PB:-75.98
PE(LYR):108.12

Loading ...

Allergan Aesthetics Unveils Layered Beauty Report on Global Shift Toward Personalized Aesthetic Care

Reuters
·
Sep 02

AbbVie Inc. Stock Underperforms Tuesday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Sep 02

Global Pharma Companies That Have Publicly Announced Trump Drug Pricing Agreements

Reuters
·
Sep 01

NetraMark Appoints Abivax Regulatory Chief Keith Fournier to Board

Reuters
·
Sep 01

States Namenda Tablets not Withdrawn for Safety or Effectiveness Reasons - Federal Register

THOMSON REUTERS
·
Aug 31

FDA: Will not Begin Procedures to Withdraw Approval of Abbreviated New Drug Applications That Refer to Namenda Products - Federal Register

THOMSON REUTERS
·
Aug 31

AbbVie to Present at Wells Fargo Healthcare Conference

Reuters
·
Aug 31

Pharma Industry Stares Down Biggest Patent Cliff in Decades

Dow Jones
·
Aug 29

AbbVie Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Aug 29

AbbVie Targets Rare Blood Disorder With New Phase 3 Etentamig Trial Plan

TIPRANKS
·
Aug 29

China's HBM Holdings H1 Revenue Rises on Progress on Mid-Late Clinical Stage Programs

Reuters
·
Aug 27

China's JW Therapeutics Interim Revenue Rises 4.7% on Carteyva Sales

Reuters
·
Aug 27

AbbVie Seeks EMA Approval for Skyrizi Subcutaneous Induction in Crohn’s Disease

Reuters
·
Aug 27

Abbvie Submits Regulatory Application to Ema for Skyrizi® (Risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

THOMSON REUTERS
·
Aug 27

AbbVie Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Aug 27

Gubra Earns USD 50 Million Milestone as AbbVie Starts Phase 2 Trial of Obesity Drug ABBV-295

Reuters
·
Aug 26

Uni-Bio Science H1 Revenue Falls 12% on Pricing Changes

Reuters
·
Aug 26

China's Shandong Xinhua Profit Drops on Domestic, International Competition

Reuters
·
Aug 25

China's Innovent Biologics H1 Revenue, Profit Rise on Strong Product Sales

Reuters
·
Aug 25

Austar Lifesciences H1 Profit Drops on Higher R&D Spending

Reuters
·
Aug 25